Compare Mesoblast Limited (MESO) vs SoundHound AI Inc (SOUN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Mesoblast Limited vs SoundHound AI Inc — how do they compare? Mesoblast Limited trades at $14.24 (market cap $1.75B), while SoundHound AI Inc trades at $5.39 (market cap $2.45B). The key difference: SoundHound AI Inc is the larger of the two by market cap, and Mesoblast Limited is trading nearer its 52-week high, SoundHound AI Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Mesoblast Limited for 15 Days and SoundHound AI Inc for 23 Days on average.
| MESO | SOUN | |
|---|---|---|
Market Cap | $1.75B | $2.45B |
Volume | 239,027 | 16,881,989 |
Sector | Health | Technology |
52-Week High | $20.96 | $21.40 |
52-Week Low | $13.19 | $5.52 |
Typical Hold Time | 15 Days | 23 Days |
Enterprise Value | $1.83B | $2.25B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MESO trades at $13.94, up 2.42% with bearish technical signals from moving averages. The company reported substantial revenue growth to $120 million in 2026 but remains unprofitable with a -47.82% net margin. Recent FDA approval for Ryoncil potency assay and completion of Phase 3 back pain trial represent significant operational milestones. Cash position remains strong at $161.16 million, though debt levels require monitoring.
While MESO shows promising revenue growth and pipeline progress, persistent losses and negative ROE present fundamental challenges. Analyst consensus leans bullish with 45% buy ratings, but technical indicators suggest near-term caution. The stock offers speculative growth potential contingent on successful commercialization and path to profitability.
SoundHound AI (SOUN) trades at $5.395, down 4.17% today, with a bearish technical signal despite recent earnings beats. The company shows strong revenue growth ($169M in 2025, $203M projected for 2026) but deep net losses (-$14M in 2025, -$137M projected). Recent developments include expansion into banking AI agents and the OASYS Edge embedded architecture launch for vehicles and smart devices, positioning for voice AI market growth.
Outlook is mixed: analyst consensus is bullish (75% buy ratings, $9.33 target) on growth prospects, but high valuation (P/S 11.41) and persistent losses pose risks. Key opportunities include market expansion and strategic deals; risks center on profitability, integration challenges, and competitive pressures in the AI sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →About SoundHound AI Inc
SoundHound AI, Inc. is a leading innovator in voice artificial intelligence, specializing in conversational intelligence technology. The company develops a platform that allows businesses to add custom voice assistants and natural language processing capabilities to their products and services, ranging from in-car systems and smart speakers to mobile apps and IoT devices. SoundHound's core technology, including its proprietary speech recognition and natural language understanding models, aims to enable fast, accurate, and deeply integrated voice AI experiences across various industries.
Read more on SOUN →
